TransCode Therapeutics (RNAZ) Earnings Date, Estimates & Call Transcripts

$0.25

0.00 (-1.84%)

(As of 09:15 AM ET)

Upcoming Earnings Date: Nov. 12Estimated
Actual EPS (Aug. 14): -$0.74 Missed By -$0.16
Consensus EPS (Aug. 14): -$0.58

RNAZ Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RNAZ Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Ad Behind the Markets

⭕ [URGENT] Buy Alert just triggered

My absolute favorite stock just hit a critical "buy now" trigger price.

Click here for the ticker >>>

TransCode Therapeutics Analyst EPS Estimates

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2024	1	($0.70)	($0.70)	($0.70)
Q2 2024	1	($0.58)	($0.58)	($0.58)
Q3 2024	1	($0.51)	($0.51)	($0.51)
Q4 2024	1	($0.16)	($0.16)	($0.16)
FY 2024	4	($1.95)	($1.95)	($1.95)

RNAZ Earnings Date and Information

TransCode Therapeutics last released its earnings results on August 14th, 2024. The reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.16. TransCode Therapeutics has generated $0.00 earnings per share over the last year. Earnings for TransCode Therapeutics are expected to grow in the coming year, from ($2.05) to ($0.47) per share. TransCode Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 12th, 2024 based off prior year's report dates.

TransCode Therapeutics Earnings History by Quarter

Time Frame

Start Date

End Date

Export to Excel

Date	Quarter	Consensus Estimate	Reported EPS	Beat/Miss	GAAP EPS	Revenue Estimate	Actual Revenue
11/12/2024 (Estimated)	-	-	-	-	-	-	-
8/14/2024	Q2 2024	($0.58)	($0.74)	($0.16)	($0.74)	-	-
5/15/2024	Q1 2024	($0.70)	($0.65)	+$0.05	($0.65)	-	-
11/14/2023	Q3 2023	($60.00)	($67.20)	($7.20)	($1.68)	-	-
8/14/2023	Q2 2023	($135.60)	($131.60)	+$4.00	($3.29)	-	-
5/15/2023	Q1 2023	-	($264.00)	($264.00)	($6.60)	-	-
3/31/2023	Q4 2022	($304.00)	($312.00)	($8.00)	($7.80)	-	-
Get the Latest News and Ratings for RNAZ and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for TransCode Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
11/14/2022	Q3 2022	($320.00)	($264.00)	+$56.00	($0.33)	-	-
8/15/2022	Q2 2022	-	($288.00)	($288.00)	($0.36)	-	-
5/16/2022	Q1 2022	-	($216.00)	($216.00)	($0.27)	-	-
3/31/2022	Q4 2021	-	($184.00)	($184.00)	($0.23)	-	-
11/15/2021	Q3 2021	-	($160.00)	($160.00)	($0.20)	-	-
8/23/2021	Q2 2021	-	$408.00	+$408.00	$0.51	-	-

TransCode Therapeutics Earnings - Frequently Asked Questions

When is TransCode Therapeutics's earnings date?: TransCode Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 12th, 2024 based off last year's report dates. Learn more on RNAZ's earnings history.
Did TransCode Therapeutics beat their earnings estimates last quarter?: In the previous quarter, TransCode Therapeutics (NASDAQ:RNAZ) missed the analysts' consensus estimate of ($0.58) by $0.16 with a reported earnings per share (EPS) of ($0.74). Learn more on analysts' earnings estimate vs. RNAZ's actual earnings.
How much profit does TransCode Therapeutics generate each year?: TransCode Therapeutics (NASDAQ:RNAZ) has a recorded net income of -$18.55 million. RNAZ has generated $0.00 earnings per share over the last four quarters.
What is TransCode Therapeutics's EPS forecast for next year?: TransCode Therapeutics's earnings are expected to grow from ($2.05) per share to ($0.47) per share in the next year.